Suppr超能文献

相似文献

1
Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.
Br J Pharmacol. 2011 Jun;163(3):499-509. doi: 10.1111/j.1476-5381.2011.01215.x.
2
Can the electrophysiological action of rosiglitazone explain its cardiac side effects?
Curr Med Chem. 2011;18(24):3720-8. doi: 10.2174/092986711796642364.
3
Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes.
Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382(3):213-20. doi: 10.1007/s00210-010-0538-1. Epub 2010 Jul 29.
4
6
Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes.
Eur J Pharmacol. 2013 Jun 15;710(1-3):10-9. doi: 10.1016/j.ejphar.2013.03.047. Epub 2013 Apr 12.
7
Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.
Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):239-46. doi: 10.1007/s00210-012-0823-2. Epub 2012 Dec 19.
8
Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.
Br J Pharmacol. 2011 Jun;163(3):496-8. doi: 10.1111/j.1476-5381.2011.01281.x.
9
Effects of thymol on calcium and potassium currents in canine and human ventricular cardiomyocytes.
Br J Pharmacol. 2002 May;136(2):330-8. doi: 10.1038/sj.bjp.0704718.
10
Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):203-10. doi: 10.1007/s00210-004-0954-1. Epub 2004 Aug 26.

引用本文的文献

1
Computational Identification of Novel Kir6 Channel Inhibitors.
Front Pharmacol. 2019 May 24;10:549. doi: 10.3389/fphar.2019.00549. eCollection 2019.
3
Drug-induced mitochondrial dysfunction and cardiotoxicity.
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18.
4
Minireview: Challenges and opportunities in development of PPAR agonists.
Mol Endocrinol. 2014 Nov;28(11):1756-68. doi: 10.1210/me.2013-1427. Epub 2014 Aug 22.
6
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.
J Lipid Res. 2012 Sep;53(9):1738-54. doi: 10.1194/jlr.R024505. Epub 2012 Jun 8.
8
Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.
Br J Pharmacol. 2011 Jun;163(3):496-8. doi: 10.1111/j.1476-5381.2011.01281.x.

本文引用的文献

2
Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
Expert Opin Investig Drugs. 2010 Apr;19(4):489-512. doi: 10.1517/13543781003640169.
4
Guide to Receptors and Channels (GRAC), 4th Edition.
Br J Pharmacol. 2009 Nov;158 Suppl 1(Suppl 1):S1-254. doi: 10.1111/j.1476-5381.2009.00499.x.
5
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Mol Pharmacol. 2009 Dec;76(6):1333-40. doi: 10.1124/mol.109.056911. Epub 2009 Sep 14.
6
Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.
J Neurochem. 2009 Jun;109(6):1800-11. doi: 10.1111/j.1471-4159.2009.06107.x. Epub 2009 May 11.
7
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.
10
Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.
Diabetologia. 2008 Apr;51(4):675-85. doi: 10.1007/s00125-008-0924-0. Epub 2008 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验